Literature DB >> 12239098

Dexamethasone and tumor necrosis factor-alpha act together to induce the cellular inhibitor of apoptosis-2 gene and prevent apoptosis in a variety of cell types.

Jeffrey C Webster1, Reid M Huber, Rebecca L Hanson, Paul M Collier, Thomas F Haws, Juliane K Mills, Timothy C Burn, Elizabeth A Allegretto.   

Abstract

Using microarray technology, we analyzed 12,000 genes for regulation by TNF-alpha and the synthetic glucocorticoid, dexamethasone, in the human lung epithelial cell line, A549. Only one gene was induced by both agents, the cellular inhibitor of apoptosis 2 (c-IAP2), which was induced 17-fold and 5-fold by TNF-alpha at 2 h and 24 h, respectively, and increased 14-fold and 9-fold by dexamethasone at 2 h and 24 h, respectively. The combination of the two agents together led to an additive increase (34-fold) at 2 h and a more than additive effect (36-fold) at 24 h. The human c-IAP2 promoter contains two nuclear factor (NF)-kappaB sites that have been shown to be required for transcriptional activation by TNF-alpha. To test whether glucocorticoids regulate the c-IAP2 gene at the level of the promoter, a reporter vector containing 947 bases upstream of the start site of transcription of the human c-IAP2 promoter was linked to luciferase [IAP(-947-+54)-LUC] and transfected into A549 cells. Dexamethasone and TNF-alpha each induced reporter activity, whereas the combination of the two agents led to greater induction of luciferase than either one alone. Truncation of the promoter region containing a putative glucocorticoid response element (GRE) at -515 [IAP(-395-+54)-LUC] or mutation of the GRE in the context of the natural promoter [IAP(-947-+54mutGRE)-LUC] resulted in a loss of dexamethasone-mediated induction of reporter activity. Although the functional NF-kappaB sites were retained in the truncated and mutant c-IAP2 promoter constructs, dexamethasone did not inhibit the TNF-alpha induction of luciferase activity, indicating that GR repression through the NF-kappaB sites did not occur. Regulation of the c-IAP2 gene is therefore unique, as GR and NF-kappaB signaling pathways are usually mutually antagonistic, not cooperative. Treatment of A549 cells with TNF-alpha and/or dexamethasone had no effect on cell death, but the two agents were able to inhibit interferon-gamma/anti-FAS antibody-mediated apoptosis. In human glioblastoma A172 cells, TNF-alpha and dexamethasone together elicited a greater than additive increase in c-IAP2 mRNA levels and also inhibited anti-FAS antibody-mediated A172 cell apoptosis. In contrast, in human CEM-C7 leukemic T cells, whereas TNF-alpha and dexamethasone treatment also led to an increase in c-IAP2 mRNA, the two agents were able to induce apoptosis on their own. However, TNF-alpha and dexamethasone were also able to blunt anti-FAS-induced apoptosis in the T cells. These data indicate that the induction of the antiapoptotic protein, c-IAP2, by glucocorticoids and TNF-alpha correlates with the ability of these agents to inhibit apoptosis in a variety of cell types.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12239098     DOI: 10.1210/en.2002-220188

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  24 in total

1.  Glycogen synthase kinase-3β is involved in ligand-dependent activation of transcription and cellular localization of the glucocorticoid receptor.

Authors:  Camila Rubio-Patiño; Claudia M Palmeri; Alba Pérez-Perarnau; Ana M Cosialls; Cristina Moncunill-Massaguer; Diana M González-Gironès; Lluís Pons-Hernández; José M López; Francesc Ventura; Joan Gil; Gabriel Pons; Daniel Iglesias-Serret
Journal:  Mol Endocrinol       Date:  2012-07-06

2.  Cell cycle-dependent expression of cIAP2 at G2/M phase contributes to survival during mitotic cell cycle arrest.

Authors:  Hyung-Seung Jin; Tae H Lee
Journal:  Biochem J       Date:  2006-10-15       Impact factor: 3.857

3.  Arsenic exposure during embryonic development alters the expression of the long noncoding RNA growth arrest specific-5 (Gas5) in a sex-dependent manner.

Authors:  Kevin K Caldwell; Alexander Hafez; Elizabeth Solomon; Matthew Cunningham; Andrea M Allan
Journal:  Neurotoxicol Teratol       Date:  2017-11-11       Impact factor: 3.763

4.  Effects of dexamethasone on small bowel and kidney oxidative stress and histological alterations in bile duct-ligated rats.

Authors:  Hayrettin Ozturk; Halil Eken; Hulya Ozturk; Huseyin Buyukbayram
Journal:  Pediatr Surg Int       Date:  2006-08-01       Impact factor: 1.827

5.  Context-dependent cooperation between nuclear factor κB (NF-κB) and the glucocorticoid receptor at a TNFAIP3 intronic enhancer: a mechanism to maintain negative feedback control of inflammation.

Authors:  Mohammed O Altonsy; Sarah K Sasse; Tzu L Phang; Anthony N Gerber
Journal:  J Biol Chem       Date:  2014-02-05       Impact factor: 5.157

6.  Dexamethasone inhibits TRAIL- and anti-cancer drugs-induced cell death in A549 cells through inducing NF-kappaB-independent cIAP2 expression.

Authors:  Youn Seup Kim; Jae Seuk Park; Young Koo Jee; Kye Young Lee
Journal:  Cancer Res Treat       Date:  2004-10-31       Impact factor: 4.679

Review 7.  Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.

Authors:  David Czock; Frieder Keller; Franz Maximilian Rasche; Ulla Häussler
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

8.  Expression of corticosteroid-binding globulin in human astrocytoma cell line.

Authors:  Larissa Pusch; Sonja Wegmann; Jack D Caldwell; Gustav F Jirikowski
Journal:  Cell Mol Neurobiol       Date:  2009-01-27       Impact factor: 5.046

9.  Function of the respiratory syncytial virus small hydrophobic protein.

Authors:  Sandra Fuentes; Kim C Tran; Priya Luthra; Michael N Teng; Biao He
Journal:  J Virol       Date:  2007-05-09       Impact factor: 5.103

Review 10.  Gene regulation by non-coding RNAs.

Authors:  Veena S Patil; Rui Zhou; Tariq M Rana
Journal:  Crit Rev Biochem Mol Biol       Date:  2013-10-28       Impact factor: 8.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.